Zevia Reports Strong Margin Gains Amid Mixed Annual Sales Performance

Published 1 hours agoZVIA

Zevia Reports Strong Margin Gains Amid Mixed Annual Sales Performance

Zevia PBC (NYSE: ZVIA) recently unveiled its financial performance for the fourth quarter and full year of 2024. The company posted fourth-quarter net sales of $39.5 million, a 4.4% uptick from the previous year, while achieving a gross profit margin of 49.2%, reflecting an 8.5 percentage point year-over-year improvement. Net loss for the quarter improved to $6.8 million, down by $2.4 million from Q4 2023, and the adjusted EBITDA loss narrowed by $3.0 million to $3.9 million. Additionally, loss per share decreased by $0.05 to $0.09 compared to the prior year period.

However, Zevia's full-year results painted a more varied picture, as net sales dropped by $11.4 million to total $155.0 million for 2024. On the brighter side, the company saw its gross profit margin rise by 1.5 percentage points, and the net loss narrowed to $23.8 million — an improvement of $4.5 million compared to the previous year. Adjusted EBITDA loss also showed progress, reducing to $15.2 million, a $3.8 million enhancement year-over-year, and the loss per share decreased by $0.07 to $0.34.

Strategically, Zevia is expanding its distribution significantly, now operating in over 4,300 Walmart locations, up from only 800 previously, according to Reuters. The company has also implemented a Productivity Initiative aimed at yielding $15 million in annual cost savings, with plans to funnel much of these savings into growth opportunities. These steps underscore Zevia's initiative to boost profitability while expanding its market reach.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Scotiabank Lowers Price Target for Geron Amid Rytelo Sales Concerns

Scotiabank Lowers Price Target for Geron Amid Rytelo Sales Concerns

5 minutes agoGERN

Scotiabank recently downgraded its price target for Geron Corporation, reflecting concerns over the sales performance of the company's blood cancer drug, Rytelo. The price target was reduced from $6.00 to $4.00, while maintaining a 'Sector Outperform' rating. This adjustment comes in the wake of Geron's fourth-quarter 2024 results, which met expectations but showed a slower-than-hoped launch momentum for Rytelo in treating lower-risk myelodysplastic syndromes (LR-MDS). This development underscores the challenges Geron faces in the competitive oncology market. The company's current stock price stands at $1.275, representing a slight decrease from its previous close. As reported by Scotiabank, the market remains vigilant following the drug's performance indicators, which play a crucial role in influencing investor sentiment. Despite the lowered price target, Scotiabank's retention of a 'Sector Outperform' rating signals sustained confidence in Geron's long-term potential. The bank's outlook suggests that while immediate sales trajectories pose worries, the broader investment case for Geron remains positive. This indicates that investors might still find value in Geron's strategic initiatives and future growth prospects.

Teradyne Declares $0.12 Dividends and Expands Share Buyback Program

Teradyne Declares $0.12 Dividends and Expands Share Buyback Program

20 minutes agoTER

Teradyne, Inc. has announced a quarterly cash dividend of $0.12 per share, continuing its regular return of capital to investors. This dividend is slated to be paid on March 14, 2025, with shareholders needing to be on record by February 14, 2025, and the ex-dividend date set for February 13, 2025. The company's annualized dividend yield stands at approximately 0.4%. In a related financial move, Teradyne is expanding its share repurchase efforts, adding up to $100 million to its existing buyback program for the remainder of 2024. This extension is part of a broader $2 billion initiative, extending beyond merely offsetting potential stock dilution from equity compensation and employee share purchases. These financial commitments highlight Teradyne's robust fiscal strategy and its dedication to delivering value to shareholders. According to Business Wire, the expansion of the share buyback program reflects the company's belief in its long-term prospects and its strategy to maximize shareholder returns.

Shopify's Stock Dips Amidst Mixed Financial Outlook

Shopify's Stock Dips Amidst Mixed Financial Outlook

35 minutes agoSHOP

Shopify's stock is under pressure in premarket trading, dropping over 6%, as the company issued its latest financial forecasts. This movement comes as Shopify projects its second-quarter revenue to grow in the mid-20% range, slightly exceeding the analysts' average expectation of 22.4%, according to Reuters. However, it's not all positive news. Shopify's projection for gross profit growth is set to rise at a high-teen percentage rate, falling short of analysts' expectations of a 20.2% increase. These mixed signals have contributed to volatility in the company's stock performance, which currently sits at $91.29 per share, showing a decrease of $3.96 from its previous close. The intraday performance has witnessed a high of $99.24 and a low of $84.9, with a significant trading volume of 19,518,304 shares. Shopify's strategic outlook remains focused on solidifying its revenue streams while managing profit margins within a competitive market. The latest trading figures underscore the market's cautious response to the company's financial guidance, emphasizing the balance Shopify seeks to maintain between growth expectations and profitability targets.

Insmed Sees Growth in ARIKAYCE Sales and Advances Brensocatib Development

Insmed Sees Growth in ARIKAYCE Sales and Advances Brensocatib Development

50 minutes agoINSM

Insmed Incorporated has reported significant growth in its financial performance, particularly in the global net product sales of ARIKAYCE. In 2024, sales reached approximately $363.7 million, a notable 19% increase from the previous year. The company anticipates this growth trend to continue, projecting global ARIKAYCE revenues to range between $405 million and $425 million in 2025, according to stocktitan.net. Alongside financial gains, Insmed is making strides in drug development. The FDA has accepted the New Drug Application for brensocatib, designed for patients with bronchiectasis, and has granted it priority review with an expected action date of August 12, 2025. Reuters reported that, subject to approval, Insmed plans to launch brensocatib in the U.S. by mid-2025, with releases in Europe and Japan set for the first half of 2026. Insmed's strategic focus includes hefty investment into product commercialization and widening its global reach. As of the end of 2024, the company held cash and securities amounting to $1.4 billion. This solid financial footing supports their ongoing plans for the U.S. launch of brensocatib and further development of clinical trial programs in 2025 as noted on Nasdaq.com. These efforts highlight Insmed's commitment to both product expansion and financial growth.